What is HC Wainwright’s Estimate for ALGS FY2024 Earnings?

Aligos Therapeutics, Inc. (NASDAQ:ALGS) – Stock analysts at HC Wainwright boosted their FY2024 earnings per share estimates for Aligos Therapeutics in a note issued to investors on Thursday, November 7th. HC Wainwright analyst E. Arce now expects that the company will earn ($9.21) per share for the year, up from their previous estimate of ($11.21). HC Wainwright has a “Buy” rating and a $75.00 price objective on the stock. The consensus estimate for Aligos Therapeutics’ current full-year earnings is ($9.82) per share. HC Wainwright also issued estimates for Aligos Therapeutics’ Q4 2024 earnings at ($1.83) EPS, Q1 2025 earnings at ($1.85) EPS, Q2 2025 earnings at ($1.95) EPS, Q3 2025 earnings at ($2.13) EPS, Q4 2025 earnings at ($2.19) EPS, FY2025 earnings at ($8.13) EPS, FY2026 earnings at ($6.82) EPS, FY2027 earnings at ($7.57) EPS and FY2028 earnings at ($7.26) EPS.

Aligos Therapeutics Stock Up 37.3 %

Shares of NASDAQ:ALGS opened at $13.99 on Monday. Aligos Therapeutics has a 52-week low of $6.76 and a 52-week high of $30.00. The stock’s fifty day simple moving average is $9.81 and its 200-day simple moving average is $12.51. The company has a market capitalization of $44.77 million, a P/E ratio of -1.05 and a beta of 2.11.

Aligos Therapeutics (NASDAQ:ALGS) last posted its earnings results on Wednesday, November 6th. The company reported ($3.07) earnings per share for the quarter, missing the consensus estimate of ($2.15) by ($0.92). The firm had revenue of $1.27 million during the quarter, compared to analyst estimates of $1.00 million. Aligos Therapeutics had a negative net margin of 1,283.19% and a negative return on equity of 114.34%. During the same period last year, the company posted ($10.25) EPS.

Institutional Trading of Aligos Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Armistice Capital LLC lifted its position in shares of Aligos Therapeutics by 5.3% in the second quarter. Armistice Capital LLC now owns 7,256,410 shares of the company’s stock valued at $2,540,000 after acquiring an additional 363,000 shares in the last quarter. Opaleye Management Inc. lifted its position in shares of Aligos Therapeutics by 25.7% in the first quarter. Opaleye Management Inc. now owns 1,630,000 shares of the company’s stock valued at $1,597,000 after acquiring an additional 333,000 shares in the last quarter. Finally, Acadian Asset Management LLC lifted its position in shares of Aligos Therapeutics by 26.1% in the second quarter. Acadian Asset Management LLC now owns 829,485 shares of the company’s stock valued at $289,000 after acquiring an additional 171,490 shares in the last quarter. 60.43% of the stock is currently owned by hedge funds and other institutional investors.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).